Prelude Therapeutics annual ebitda
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics EBITDA Growth & History (PRLD)
Prelude Therapeutics's calculated EBITDA was −$102.9M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$102.9M | $35.1M | — |
| 2024 | 2024-12-31 | −$137.9M | −$6.8M | — |
| 2023 | 2023-12-31 | −$131.1M | −$8.9M | — |
| 2022 | 2022-12-31 | −$122.2M | −$9.4M | — |
| 2021 | 2021-12-31 | −$112.8M | −$54.6M | — |
| 2020 | 2020-12-31 | −$58.2M | −$30.5M | — |
| 2019 | 2019-12-31 | −$27.7M | — | — |
Prelude Therapeutics quarterly ebitda
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$15.1M | $16.7M | — |
| Q1 2026 | 2026-03-31 | −$13.8M | $20.4M | — |
| Q4 2025 | 2025-12-31 | −$16.9M | $16.4M | — |
| Q3 2025 | 2025-09-30 | −$20.0M | $14.0M | — |
| Q2 2025 | 2025-06-30 | −$31.8M | $5.0M | — |
| Q1 2025 | 2025-03-31 | −$34.2M | −$254,000 | — |
| Q4 2024 | 2024-12-31 | −$33.3M | $3.7M | — |
| Q3 2024 | 2024-09-30 | −$34.0M | −$865,000 | — |
| Q2 2024 | 2024-06-30 | −$36.7M | −$4.6M | — |
| Q1 2024 | 2024-03-31 | −$33.9M | −$5.1M | — |
| Q4 2023 | 2023-12-31 | −$37.0M | −$4.0M | — |
| Q3 2023 | 2023-09-30 | −$33.1M | −$3.0M | — |
| Q2 2023 | 2023-06-30 | −$32.1M | −$3.0M | — |
| Q1 2023 | 2023-03-31 | −$28.8M | $1.1M | — |
| Q4 2022 | 2022-12-31 | −$33.0M | −$303,000 | — |
| Q3 2022 | 2022-09-30 | −$30.1M | $501,000 | — |
| Q2 2022 | 2022-06-30 | −$29.1M | −$1.4M | — |
| Q1 2022 | 2022-03-31 | −$30.0M | −$8.2M | — |
| Q4 2021 | 2021-12-31 | −$32.7M | −$13.4M | — |
| Q3 2021 | 2021-09-30 | −$30.6M | −$12.6M | — |
| Q2 2021 | 2021-06-30 | −$27.7M | −$16.4M | — |
| Q1 2021 | 2021-03-31 | −$21.8M | −$12.2M | — |
| Q4 2020 | 2020-12-31 | −$19.3M | — | — |
| Q3 2020 | 2020-09-30 | −$18.0M | — | — |
| Q2 2020 | 2020-06-30 | −$11.3M | — | — |
| Q1 2020 | 2020-03-31 | −$9.6M | — | — |
Prelude Therapeutics ebitda trends
Over the last five fiscal years, Prelude Therapeutics's ebitda decreased from −$58.2M to −$102.9M, a change of −$44.6M. The latest reported quarter, Q2 2026, shows −$15.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...
